Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 6/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751975 | 0.91 | CYP3A4 (0.42) | CYP3A4CHRM5CHRM1ESR2REN | |
| SCHEMBL1752582 | 0.88 | ACACB (0.40) | CHRM5CHRM1ESR2NR1H2CHRM2 | |
| SCHEMBL5941947 | 0.87 | CHRM5 (0.40) | CHRM5CHRM1ESR2NR1H2CHRM2 | |
| SCHEMBL5941814 | 0.85 | CHRM5 (0.45) | CHRM5CHRM1ESR2NR1H2CHRM2 | |
| SCHEMBL3044833 | 0.82 | CHRM5 (0.43) | CHRM5CHRM1ESR2NR1H2CHRM2 | |
| SCHEMBL3197517 | 0.80 | SLC6A3 (0.54) | CHRM5CHRM1ESR2NR1H2CHRM2 | |
| SCHEMBL4685482 | 0.80 | CYP3A4 (0.45) | CYP3A4CHRM5CHRM1REN | |
| SCHEMBL1751769 | 0.80 | ESR2 (0.39) | ESR2NR1H2MEN1KMT2AGPR119 | |
| SCHEMBL3194232 | 0.79 | SLC6A3 (0.57) | ESR2NR1H2SLC6A2SLC6A3 | |
| SCHEMBL1750649 | 0.78 | CHRM5 (0.48) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | CYP3A4 441/4885CHRM5 320/4885CHRM1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.